Revance Therapeutic (RVNC) PT Lowered to $11 at Piper Sandler
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
William Blair Reviews Revance Therapeutic (RVNC) EPS
May 13, 2024 7:04 AM EDTWilliam Blair analyst Tim Lugo reiterated an Outperform rating on Revance Therapeutic (NASDAQ: RVNC).
The analyst comments "Revance announced first quarter 2024 DAXXIFY revenues of $22.1 million, approximating our estimate of $22.2 million and just shy of consensus of $23.5 million. While the first quarter is typically... More
